Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic value of serum C4d, PLA2R, THSD7A antibodies and tacrolimus efficacy in idiopathic membranous nephropathy
ChiCTR2000033766Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Jul 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tacrolimus in membranous glomerulonephritis (MGN) (2 arms), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoints: 24-hour urinary protein quantity and serum albumin. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on ChiCTR2000033766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033766.